Thu, Oct 23, 2014, 1:36 AM EDT - U.S. Markets open in 7 hrs 54 mins


% | $
Quotes you view appear here for quick access.

CombiMatrix Corporation Message Board

bitesr 21 posts  |  Last Activity: Oct 19, 2014 3:39 PM Member since: Apr 22, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    This new CEO is pathetic

    by pretzel223 Oct 17, 2014 12:31 PM bitesr Oct 19, 2014 3:39 PM Flag

    Should be dead by the end of the year. As the Gertrude Stein quote goes, "there's no there, there." As for money bags Kirk, don't see him stepping up to the plate. No leadership there as he plays the fiddle while his empire burns, just like Nero.

  • Reply to


    by la.taupe Oct 16, 2014 4:04 AM bitesr Oct 16, 2014 10:25 PM Flag

    How about $19? Genius, right? That is irrelevant to me because what's important is where it closes on Friday. All my shares are being used to cover the 20 strike options that expire this weekend. I sold the options for 2 each. So if it closes above 20 tomorrow I get $2 per share of income (already received) and $12 per share of capital gain on my taxes (and yes $20 per share proceeds). If it closes under 20, I get $2 share of income and keep my shares.

    I'm hoping for the latter so that I can play it again, Sam. I was watching this in amazement as it went up each day to 24 to, in my opinion, over-bought territory. I planned to let it ride and simply use my shares to cover because I wasn't going to chase this seemingly irrational price rise to buy back the options. My DRTX is "only" 23+ because of the take-out offer and was bought at the same price and time as TTPH. So this time, I hope to play it again with another option round, I hope with better timing. After all the rest of the market looks pretty dismal.

  • Reply to


    by drionache Oct 16, 2014 12:26 PM bitesr Oct 16, 2014 2:26 PM Flag

    Didn't make money with EXAS but did with the others you listed. Already own CTIX at about 50% lower-than-current price. Also own CEMP and still own and only up around 40% so far with it. Got to love small pharmas that have anti-infectives instead of the ones with oncology products in development. But I'm not predicting how the market shares will pan out for competing anti-infectives. Much will depend on how resistance patterns develop and that cannot be predicted. Antibiotics have always been the poor stepchild in Big Pharma so I'm happy to see this category gaining investor traction.

  • I was wondering about the big rise on Friday with no news. Volume up and share price up almost 10%. Obviously word leaked out and those who drove up the price on Friday had inside info of the deal (perhaps not the exact numbers of the deal). Either way, I hope the SEC files insider trading lawsuits. Fortunately, I was too busy to follow the stock market on Friday and did not sell. But if I had sold, I'd be screaming for justice.

  • So if the shorts/detractors think Zo is such a sheet product that is going nowhere and soon to be taken off the market, why have there been two ANDA filings? I guess you guys are smarter than the entire generic industry, eh?

  • This is now a momentum play. Higher than normal volumes and upward bias in price. In the short term this will peter out. The longer term depends on NDA filing and approval. I now have over a 2.5X gain in about 18 months hold so I'll take profits now. I don't think this upswing can last and I'll buy back (always difficult to time this) when or if I see a significant dip. I didn't sell the shares, just covered call options that could have my shares called away if it closes over 20 at Oct options expiration and I'll have effectively sold at 22. But my concern is how poorly DRTX behaved after FDA approval. Bought both at the same time and at the same 8 per share price. In hindsight I should have sold DRTX right after approval so I'm trying to learn from past mistakes.

  • bitesr Sep 23, 2014 1:01 PM Flag

    Also own CEMP. TTPH and DRTX. You didn't see those 3 companies putting out stupid press releases did you? Why is CTIX different in the need to put out stupid press releases? All of the companies are addressing the same market segments and the issues of drug resistance. But only CTIX played to stupid investors with a stupid press release. We can all read the news and know that each of the companies you mentioned (and that I also own) are addressing the same market segment. The art of seduction is not to be naked on the first date but to leave a little to the imagination.

  • Reply to


    by mark199604 Sep 23, 2014 11:46 AM bitesr Sep 23, 2014 12:49 PM Flag

    heck no. Run but out-of-touch morons. It is filled with little circles. Those are 10 foot pole marks.

  • bitesr Sep 19, 2014 3:17 PM Flag

    That was the dumbest press release I've ever read. Do you think that we (shareholders) are idiots? I read the White House announcement. CTIX is wrong. The $20Mil prize is irrelevant to what CTIX has. The prize relates to rapid tests for antibiotic resistance and susceptibility. It has nothing to do with another antibiotic. I'm long this stock, have an unrealized gain but I'm worried about the complete idiots running the asylum. When you get stupid hype, as today's press release is, it reflect poorly on management. I'll likely sell after I get back Stateside and have time to make some portfolio moves. No matter how good their product might be, putting out complete idiot press releases is unforgivable.

  • bitesr Sep 4, 2014 5:10 PM Flag

    Who gives a flying fig about what bought and paid for media or politicians say. Words are meaningless here. Actions speak far more than words. And the action that speaks the loudest is the filing of an ANDA and subparagraph 4 certification to try to market a generic Zo. Why would a generic invest its time and money in Zo to try to get generic exclusivity if Zo is about to be pulled from the market, as the pundits and wags have alleged? It's more evidence of our corrupt system of the media and politics that are bought and paid-for by money interests (read: Purdue and others). This illustrates why Congress needs to pass strict and severe campaign finance reform because the corrupt crony system we have no only makes the rich richer and the middle class disappear.

  • Reply to

    Zogenix/Daravita vs Actavis Lawsuit

    by ogvek Sep 4, 2014 4:17 PM bitesr Sep 4, 2014 4:58 PM Flag

    This is not material to ZGNX. Despite what the pundits and wags say, any generic can obtain FDA approval after Oct 2016 because that is when the 3 years of Hatch Waxman exclusivity ends. But by filing a lawsuit now (Sept), this means there will be no generic approval until March 2017, at the earliest. That just gave us 5 extra months before a generic can be approved. The incentive for Actavis to fight the lawsuit is it gets 180 day generic exclusivity. By generic exclusivity I mean that can be only two Zo products on the market before the hodes of generics invade the market. And this is not based on the male bovine excrement , so-called abuse deterrent formulation make an appearance.
    So while the pundirs and wags will try to spin this negatively, it is actually positive for ZGNX.

  • Reply to

    Dream Team

    by longstrongstupid Aug 26, 2014 7:46 PM bitesr Aug 28, 2014 12:35 PM Flag

    Are you referring to the stock promoters who screwed up GALE? That saga showed what a scam seeking alpha is. But what caused the SEC investigation was the former CEO and various Board members to hire the Dream Team to pump up the stock by their social media (such as this message board) and seeking alpha articles and then the insiders sold at the high.
    The take-home lesson is that actions speak louder than words, particularly when unknown others are only talking the talk but the insiders are running in the other direction.

  • bitesr Aug 21, 2014 7:31 PM Flag

    Who gives a flying fig about Roth? Or any other numb #$%$ banker for that matter? We're quite capable of evaluating such stock for ourselves, particularly those of us who work in this industry.

  • This is disturbing that it took this company 8+ years to get an allowance on a barely enforceable method of treatment claim patent. Most pharmas don't bother to partner when the only protection is a method of treatment and not a compound or composition/formulation. According to the press release (it smells of hype to put out a PR on an allowance) the patent term is until 2026. That means the patent application was filed about 8 years ago in 2006. Why has it taken so long to get the patent.?Why has it taken over 8 years to to get to phase 1? Something smells here and this is my biggest losing position (I'm long too many shares).

  • bitesr Aug 16, 2014 1:26 PM Flag

    Idiotic suggestion. SA author is guilty of slander. So what? The article clearly was filled with hedge mud-slinging and no actual facts. Anyone with basic reading comprehension could see that. I took advantage of the article and bought shares. So I should be sued because I purchased shares? And those fools who sold should be entitled to compensation for their own decision? We are not in a nanny state. Take responsibility for your decisions. No one held a gun to your head and told you to sell. If you could not comprehend the article, blame your poor elementary school education.

    I did sell in the 12-13 range because I was worried that the stock went up without a catalyst or news. I have since bought back And I'm just some retail s_chmuck who invests for himself. What's the big deal here? The SA article just showed how stupid the short or bear case was. Believe that and I have a bridge to sell you.

  • Reply to

    class action..

    by jdunef Aug 15, 2014 4:45 PM bitesr Aug 16, 2014 1:17 PM Flag

    These are non-material nuisance suits by the lowest form of legal #$%$. Let the D&O insurance carrier get them dismissed. And you cannot counter-sue under Noerr Pennington. No one with any industry knowledge cares about them.

  • Reply to

    The Ballgame is Over

    by bitesr Jul 31, 2014 7:34 PM bitesr Aug 1, 2014 5:38 PM Flag

    Seriously? Lack of knowledge? It doesn't matter how much money is in the bank. When there is no more revenue, whatever's in the bank runs out fast. BK will be chapter 7 liquidation (not 11 restructuring) and the common shareholders take last. You can believe all the male bovine excrement put out in press releases but the FDA shuts you down and imposes jail time if it's directives are violated. Forrest Gump was right, stupid is as stupid does.

  • by bitesr Jul 31, 2014 7:34 PM Flag

    The game is over. CBMX will be taken off the market. The FDA is requiring regulation and prior approval of all CLIA lab home-brew tests. Next stop is BK.

  • Reply to

    Cxdc fights back legal cades

    by mjafarkhan Jul 30, 2014 1:47 PM bitesr Jul 30, 2014 9:06 PM Flag

    Muddy Waters is run by a lawyer who knows to put out actual evidence, not innuendo and mudslinging that was done to CXDC. Then the Pavlovian response by the class action shareholder plaintiff's bar is in response to the share price drop but they didn't do an investigation. Most companies have D&O insurance to cover this form of nuisance. The legal fees will be low because there is a high pleading standard and there's no evidence to support the pleading standard. As for the former SEC lawyer hype, how do you know he/she wasn't fired from the SEC for incompetence and instead of following the well-trodden path to major NY law firms (like Shearman) where he couldn't get a job, had to open up his own ambulance-chasing shop?

  • Reply to

    Cxdc fights back legal cades

    by mjafarkhan Jul 30, 2014 1:47 PM bitesr Jul 30, 2014 3:55 PM Flag

    These suits will be dismissed pronto. There's no evidence. It's all male bovine excrement bluster. By the way it's spelled Shearman. I've worked with them on some deals.

1.46-0.02(-1.35%)Oct 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.